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ABSTRACT 
The bone marrow niche is composed of a complex set of cellular, chemical, 
structural and physical cues that are required to maintain viability and function of 
the hematopoietic system. [1-5]. The source of all differentiated blood cells, the 
hematopoietic stem cell (HSC), is housed within the protective confines of the 
bone marrow where the complex microenvironment regulates its ability to 
undergo self-renewal or to differentiate into all of the mature functional blood cell 
types that constitute the hematopoietic system [4-7]. Engineering an artificial 
bone marrow that reconstitutes the critical inductive cues of naturally occurring 
bone marrow in vivo that maintains them in vitro could lead to new models of 
hematopoietic diseases, as well as enable expansion of bone marrow for 
therapeutic transplantation and manufacturing of differentiated blood cell 
replacements. It has proven difficult, however, to identify or combine the correct 
set of biomaterials and biological signals necessary to recreate the complex bone 
marrow microenvironment or to maintain functional, multi-potent, self-renewing 
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HSCs in culture [8-13]. Here, we describe a microfluidic bone marrow-on-a-chip 
created in vivo by combining microsystems and tissue engineering strategies to 
produce bone that contains a complex bone marrow niche. The hematopoietic 
compartment of the engineered bone marrow (eBM) has a distribution of HSCs, 
hematopoietic progenitor cells, and differentiated blood cell types that is virtually 
identical to natural marrow. Moreover, these hematopoietic populations are 
retained in normal proportions and the HSCs maintain their full regenerative 
capacity when the eBM is explanted and cultured in the microfluidic bone marrow 
chip in vitro. After four days of culture on-chip, hematopoietic cells isolated from 
the eBM engrafted a lethally-irradiated mouse, reconstituted the compromised 
bone marrow, and fully restored all differentiated blood cell lineages. Preliminary 
work with human umbilical cord blood (hCB) suggests that the bone marrow-on-
a-chip platform may be extended beyond the mouse to support human HSCs and 
hematopoietic progenitors in vitro. This ability to engineer a complex bone 
marrow niche that is capable of maintaining functional HSCs offers new tools for 
expansion of cells for transplantation, manufacturing. differentiated blood cells , 
evaluation of drug efficacy and toxicities, and study of hematopoietic diseases. 
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INTRODUCTION 
Hematopoietic stem cells (HSCs) are multi-potent cells defined by their 
ability to undergo self-renewal, remain undifferentiated or to develop into all of 
the mature functional blood cell types that constitute the hematopoietic system 
[1-4]. In an adult, bone marrow serves as the primary reservoir of HSCs and 
hematopoietic progenitor cells. Maintenance of an HSC in its delicate stem-like 
state requires a complex set of cellular, chemical, structural and physical cues 
found almost exclusively in the complex bone marrow microenvironment or niche 
(Figure 1) [1, 2, 5-7]. 
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Figure 1 - Bone Marrow Microenvironment. Depiction of the complex physical, 
chemical , cellular and architectural features influencing HSCs and hematopoiesis in 
bone marrow microenvironment. Adapted from Wang et a1.[2] 
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Given the critical importance of bone marrow in preserving and promoting 
hematopoietic function , engineering an artificial bone marrow that reconstitutes 
the essential inductive cues of naturally occurring bone marrow in vivo, that can 
be maintained in vitro would be of great value. An engineered bone marrow could 
serve as a platform to develop in vitro models of hematopoietic diseases, as well 
as enable expansion of blood components for therapeutic transplantation or test 
the efficacy and safety of drugs on individual patent marrow aspirates or 
peripheral blood samples. It has proven difficult, however, to identify or combine 
the correct set of biomaterials and biological signals necessary to recreate the 
complex bone marrow microenvironment or to maintain functional, multi-potent, 
self-renewing HSCs in culture [8-13]. 
Bone Tissue Engineering 
In vivo ectopic bone formation has long been an active area of research. 
Previous work has demonstrated that implantation of demineralized bone into live 
animals results in the formation of new bone. It has been shown that new bone 
created from demineralized bone substrates occur through a step-wise process 
consisting of cellular recruitment, connective tissue deposition , vascularization, 
followed by the induction of multipotent, undifferentiated mesenchymal cells [14] 
to form chondroprogenitors, under low oxygen tension , and osteoprogenitors, 
under high oxygen tension [15-17]. Provided the appropriate environmental cues 
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or milieu, chondroprogenitors undergo further differentiation into chondrocytes, 
serving as cartilage producers, while osteoprogenitors differentiate into 
osteoblasts, initiating the process of mineralization and bone formation. 
Ultimately, the hematopoietic (monocyte)-derived osteoclasts arrive at the site of 
bone deposition to facilitate bone resorption and remodeling. 
Investigators utilizing demineralized bone powder (DBP) to study ectopic 
bone formation in vivo often employ the strategy of introducing the bone-inducing 
materials intramuscularly or surgically into small bowel mesentery [16, 18-20]. 
While these strategies have resulted in bone and bone marrow formation, the 
limited marrow that forms within the tissue is heavily infiltrated with adipocytes, a 
cell type shown to have inhibitory effects on hematopoiesis [21], while displaying 
correspondingly low density of blood cells. Moreover, implantation of the bone-
inducing materials inside of tissues (muscle, mesenchyme, etc.) results in bone 
of ill defined shape that is fully integrated into the tissue, rendering a structure 
that is not easily accessible or extractable from the animal. 
DBP initiates bone formation largely through its osteoconductive 
properties, supplying a scaffold or surface on which new bone growth can be 
initiated. Depending on the preparation method of DBP, it can also be modestly 
osteoinductive, a property defined by the initiation of de novo bone formation 
through the recruitment and differentiation undifferentiated mesenchymal cells to 
become osteoprogenitor cells and ultimately bone producing osteoblasts [16]. 
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The prototypical osteoinductive substrates include the family of bone 
morphogenic proteins (BMPs) , a class of proteins originally discovered in bone 
powder [22]. While structurally similar, the individual isoforms are expressed 
during different stages of bone formation, suggesting differences in activity and 
function over the course of osteogenesis. Of the 30 BMPs identified, 5 have 
known osteoinductive properties (BMP-2, -4, -6, -7, and -9), stimulating 
endochondrial and intermembranous ossification [23]. BMP-2, for example, has 
been shown to be a potent stimulator of mesenchymal cell differentiation into, 
and maturation of, osteoblasts, thus facilitating the maintenance of normal bone 
mass [24]. Whereas, the expression of BMP-4 is reduced when cartilage 
resorption predominates and expressed at high levels during active osteogenesis 
[25]. Given the clinical interest in osteoinductive and osteoconductive materials 
for bone grafts and other orthopedic applications, there exist FDA-approved 
biomaterials consisting of bone matrix, natural, recombinant and synthetic 
structural proteins, and in some cases, BMPs to support ectopic bone formation 
in patients [20]. 
Organization of the Hematopoietic System 
The hematopoietic system is organized in a hierarchical structure, 
whereby the most primitive of all blood cells, the HSC, serves as the cellular 
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precursor to all functional, differentiated blood cell types (Figure 2). The process 
of step-wise differentiation that occurs throughout hematopoiesis creates 
functional branch points in the hierarchy, signifying a restriction in developmental 
potential. A differentiating hematopoietic cell will pass through a series of 
potential-restricting branch points until a state of complete or terminal 
differentiation is achieved, producing mature, lineage-committed functional blood 
cell. 
Under normal circumstances, the hematopoietic system is responsible for 
producing approximately one trillion blood cells per day in response to the needs 
of the body [26]. The ability to produce staggering quantities of many different 
blood cells types in a continuous and coordinated fashion is facilitated by this 
hierarchical structure. The step-wise differentiation behaves much like a signal 
transduction that employs a cascade of events to amplify the downstream effect. 
This results in an agile system characterized by rapid actuation and the potential 
for large-scale production of a given cell type. Furthermore, this structure offers 
the inherent benefit of requiring only a limited pool of self-renewing HSCs, while 
the more restricted progenitor cells with greater proliferative potential drive the 
production of differentiated cells, achieving optimal potential for self-renewal and 
differentiation. 
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Figure 2 -Hematopoiesis. Depiction of the hierarchical structure of hematopoiesis. All 
blood cells originate from a multipotent, self-renewing HSC and undergo a process of 
step-wise commitment, restricting the cell's potential while moving towards a terminally 
differentiated state (on right). 
Hematopoietic Stem Cells and the Bone Marrow Niche 
Postulated first in 1978, Schofield hypothesized that in order for a stem 
cell to remain undifferentiated, multipotent and capable of self-renewal, the cell 
must remain in a defined environment, or niche, that facilitates interactions with 
other cells and biological entities to regulate its fate, preventing it from 
differentiating and loosing its "immortality" [27]. Since its initial proposal, 
Schofield's stem cell niche hypothesis has largely been upheld. 
In the adult, a large majority of the body's limited pool of HSCs resides 
and even seeks out, or 'homes' to, the bone marrow. There has been a great 
effort to define and characterize the anatomically defined, specialized regions or 
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niches within the bone marrow that selectively support and regulate defined 
blood cell populations, especially the HSC and hematopoietic progenitors [28-
32]. The two most widely studied anatomical sites of the bone marrow shown to 
harbor and maintain HSCs include the endosteal and perivascular niches [33]. 
Endosteal Niche 
The endosteal niche, defined as the interface between the osteoblast-lined 
surface of the bone and the inner marrow cavity, is a site within the bone marrow 
where transplanted HSCs have been shown to home to or localize [34], and is 
critical to the retention of HSCs through ligand-receptor interactions including N-
cadherin [35] CXCL 12 (stem cell derived factor-1, SDF-1)- CXCR4 [36, 37], and 
Ang1 - Tie2 [38]. Through a multitude of mechanisms including secretion of 
cytokines like granulocyte-colony stimulating factor (G-CSF) [39], expression 
HSC-supporting genes and signaling pathways including Wnt [40, 41] and Notch 
[42, 43], among many others [44], local regulation of calcium [45], and even 
response to input from the sympathetic nervous system [37], osteoblasts have 
been shown to function as positive regulators of HSCs [46]. 
To illustrate the integral role of the osteoblast in the HSC-supporting 
endosteal niche, transgenic mice that were designed to have increased numbers 
of osteoblast cells [35] or increased trabecular bone content [4 7] showed a 
concomitant increase in HSCs in the bone marrow. Selective depletion of 
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osteoblasts, on the other hand, resulted in impaired bone marrow or 'medullary' 
hematopoiesis, shifting the localization of HSCs and the burden of hematopoiesis 
to extramedullary sites (liver and spleen) to compensate for the apparent 
disruption in the endosteal niche [48]. 
The importance of osteoblasts and the endosteal niche to hematopoietic 
regulation is, perhaps, not surprising when considering the coordinated 
development of bone and blood illustrated by mammalian developmental biology 
[1 ], as well as heterotopic and ectopic bone formation [15]. Consider, for 
example, the morphogen, BMP4, known to that play a critically important role in 
osteoinduction and osteogenesis. In addition to influencing bone development, it 
has been shown to participate in embryonic specification of ventral mesoderm 
and the early commitment to a hematopoietic fate [49, 50]. In the adult setting, 
when BMP4 is genetically manipulated to impair its activity, the hematopoietic 
niche is disrupted, disrupting with the maintenance of HSCs in the bone marrow 
[51]. 
Perivascular Niche 
Beyond the endosteal niche, the perivascular niche is a distinct site within 
the bone marrow that has also been implicated in HSC maintenance and 
regulation [31, 52]. With the advancement in imaging technology and genetic 
tools that enable lineage tracing experiments and cell-type specific genetic 
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modulation, defining and characterizing the HSC and hematopoietic progenitor 
niche or niches has become ever more precise. Conditional deletion of stem cell 
factor (SCF), a long established regulator of HSC maintenance in the bone 
marrow [53 , 54], from distinct cell types within the bone marrow demonstrated 
that ablation of SCF expression in the perivascular compartment (in both 
perivascular endothelial and mesenchymal cells) impaired HSC maintenance in 
the bone marrow. However, deletion of this canonical HSC supporting factor from 
osteoblast cells had no effect on the bone marrow's ability to maintain HSCs [55]. 
To gain deeper insight into the differing roles of the unique hematopoietic 
niches in the bone marrow, a systematic study of another established player 
implicated in the support, regulation and homing of HSCs to the bone marrow, 
chemokine CXCL 12 (or SDF-1) expression, was conducted . The analysis 
demonstrated that perivascular endothelial cells are important for HSC 
maintenance, while perivascular stromal cells play a key role in HSC and 
progenitor retention. Osteoprogenitors of the endosteal niche were shown to be 
required for the maintenance of early lymphoid progenitors , but not HSCs or 
myeloid-erythroid progenitors [32]. This work underscores the complexity and 
multiplicity of critical microenvironments or niches within the bone marrow that, 
together, tightly regulate the hematopoietic system. 
Given the interdependence of distinct niches within the bone marrow 
required to successfully support the continuum of the hematopoietic system, 
employing a reductionist approach and recreating individual niches or elements 
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of defined niches in isolation from the complex bone marrow milieu would 
inevitably fail to recreate all functions of the bone marrow, especially the delicate 
process of HSC hematopoietic progenitor maintenance and regulation. 
Therefore, de novo formation and true recapitulation of natural bone marrow is 
essential to fully harness the power of the bone marrow as the home of 
hematopoietic system. 
Our aim is to combine microsystems and tissue engineering strategies to 
produce bone that contains the full complexity of the bone marrow niche. By 
designing a biocompatible implantable device to serve as both a container and 
mold for the bone inducing materials in vivo, we intend to influence the direction 
of cellular ingrowth into the material and impose structural constraints that shape 
the architecture of the resulting bone. Furthermore, the implantable device will 
facilitate intact removal of the tissue construct for maintenance in vitro. We 
believe that this systems-level approach to tissue engineering will enable the 
creation of an autonomous, miniaturized bone marrow construct to enable the 
~ study of whole bone marrow and the hematopoietic system in vitro. 
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METHODS 
Engineering bone marrow 
Microfabrication of PDMS devices for implantation 
Demineralized bone powder (DBP) was prepared from femurs harvested 
from adult CD-1 mice. The femurs were washed in sterile water, extracted with 
absolute ethanol, and dehydrated with ether. The bones were crushed with a 
mortar and pestle and demineralized in 0.5 N HCI (50 mUg) for 3 hours at room 
temperature. After demineralization, DBP was washed with sterile water, 
extracted with absolute ethanol, dehydrated with ether, and was passed through 
a sieve with 250 mm pores. To prepare bone inducing materials, 3 mg DBP was 
mixed with 30 mL solution of type I collagen gel (3 mg/mL, Cellmatrix Type 1-A, 
Nitta Gelatin Inc.), 100 ng BMP2 (Alpha Diagnostic Inti. Inc.), and 100 ng BMP4 
(Alpha Diagnostic Inti. Inc.). The mixture was placed in the central cylindrical 
cavity (1 mm high x 4 mm diameter) of the device (Fig. 1A, B) was fabricated 
from polydimethylsiloxane (PDMS) formed from pre-polymer (Sylgard 184, Dow 
Corning) at a ratio of 10:1 base to curing agent. 
Animals 
The PDMS devices were filled with the bone-inducing materials and 
implanted subcutaneously on the backs of 8-20 weeks old CD-1 mice (Charles 
River Laboratories) or C57BU6-Tg(UBC-GFP)30Scha/J (Jackson Laboratories) 
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mice that express green fluorescent protein (GFP) under the ubiquitin C promoter 
in all cells, rendering an eBM that express GFP in all of its cells. The devices 
were sutured onto the surface of the muscle in the subcutaneous space on the 
back of a mouse under anesthesia (2-4% isoflurane). Four to 8 weeks after 
implantation, the engineered bone marrow (eBM) was surgically removed from 
the mouse for subsequent characterization. 
Histology 
Following harvest, eBM and mouse femurs were fixed in 4% 
· paraformaldehyde for 48h at 4 °C. The tissue construct was transferred into 70% 
ethanol for storage. Once fixed, tissues were decalcified (Richard-Allen Scientific 
Decalcification Solution, Thermo Scientific), embedded in paraffin, sectioned and 
stained with hematoxalin and eosin (H&E). 
I mmunohistochem is try 
Paraffin-embedded sections were deparaffinized and re-hydrated through 
a combination of washes in xylene and ethanol (xylene, xylene:ethanol (1: 1 ), 
100% ethanol, 95% ethanol, 75% ethanol, 100% de-ionized water) . Antigen 
retrieval was completed (Rodent Decloaker, Biocare Inc.) followed by blocking 
and staining with primary antibodies, anti-mouse CXCL 12 (eBioscience) and anti-
mouse CXCR4 (Novus Biologicals) for 2 hrs at room temperature. Sections were 
stained with horseradish peroxidase (HRP) followed by Dab betazoid (Biocare 
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Inc). Sections were counterstained with hematoxalin and dehydrated in a series 
of ethanol and xylene washes. 
Micro-computed tomography (micro-CT) 
eBM harvested from mice 4 and 8 weeks after device implantation were 
fixed for 48 hours in 4% paraformaldehyde (PFA) and stored in 70% ethanol at 
4°C. For comparison , vertebrae were harvested from the same mice 
immediately following device removal and were handled in a similar fashion. 
Both the eBM and vertebrae were imaged (in 70% ethanol) with an XRA-002 X-
Tek MicroCT system. X-ray transmission images were acquired at 55kV and 
2001-JA and the 30 reconstructions were performed using CT-Pro (Nikon 
Metrology); surface renderings were generated using VGStudio Max. 
Elemental mapping 
eBM and vertebrae harvested and fixed as described for micro-CT were 
serially dehydrated into 1 00% ethanol and then embedded in Spurr's resin and 
sectioned at the desired imaging plane using a slow speed diamond saw. The 
resulting sections were polished with silicon carbide papers down to P1200, 
sputter coated with gold or carbon and examined using a Tescan Vega-3 
scanning electron microscope equipped with a Bruker X-Fiash 530 energy 
dispersive spectrometer (EDS). All backscattered SEM images, EDS spectra, 
and elemental maps were acquired at 20keV accelerator voltage. For calculating 
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elemental composition of both the sectioned implant and vertebra samples, 10 
point spectra from the surface of each sample were acquired and the percent 
phosphorus and calcium content was determined by averaging the obtained 
values± standard error of the mean (S.E.M). 
Flow cytometry 
To harvest hematopoietic cells from the eBM, the tissue construct was cut 
into small pieces and digested using 1 mg/ml collagenase for 30 min at 37 °C. 
The digested tissue was filtered to remove boney tissue. Bone marrow was 
harvested from mouse femurs (mBM) by flushing the marrow cavity with a 21 G 
needle. 
The hematopoietic cell composition of eBM and mBM was analyzed by 
multicolor flow cytometry analysis using an LSRFortessa (BD Bioscience) with 
antibodies directed against characteristic blood surface antigens (Tables 1, 2). 
Cell viability was assessed by propidium iodide (PI) staining. 
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Hematopoietic Stem Cell Hematopoietic Progenitor Hematopoietic Lineage 
(HSC) Antibodies Antibodies antibodies 
Lineage Cocktail (eFiuor450) Lineage Cocktail (eFiuor 450) Ter119 (APC-eFiuor780, 
(CD3, CD45R, CD11 b, (CD3, CD45R, CD1 1 b, erythrocytes) 
Ter119, Gr1) Ter119, Gr1) 
Sca1 (APC) CD34 (PE-Cy5) CD45 (Pacific Blue, 
lymphocytes) 
cKit (CD117, APC-eFiuor780) CD135 (PE) CD19 (APC, B-ee/Is) 
CD150 (PE) CD3 (APC-Cy?, T-ee/Is) 
CD48 (APC) Mac1 (PE, macrophages) 
Gr1 (APC, granulocytes) 
Table 1. Fluorescently labeled flow cytometry antibodies for mouse 
hematopoietic cells. The fluorescent antibodies listed in the table will be used to 
evaluate the presence of mouse hematopoietic stem, progenitor and lineage-restricted 
differentiated populations within the eBM, Dexter-type culture and normal bone marrow. 
Hematopoietic Stem Cell (HSC) Hematopoietic Progenitor Antibodies 
Antibodies 
HLA-ABC (Pacific Blue) HLA-ABC (Pacific Blue) 
Lineage Cocktail (FITC) Lineage Cocktail (FITC) 
(CD3, CD14, CD16, CD19, CD56) (CD3, CD14, CD16, CD19, CD56) 
CD38 (PE-Cy?) CD34 (APC) 
CD190 (PE) 
Table 2. Fluorescently labeled flow cytometry antibodies for human 
hematopoietic cells. The fluorescent antibodies listed in the table will be used to 
evaluate the presence of human hematopoietic stem and progenitor cells within the eBM 
and dish culture. 
In vitro microfluidic culture system 
Microfluidic device 
Microfluidic devices for in vitro culture of eBM consist of three PDMS 
layers separated by two porous PDMS membranes (1 00 mm diameter pores; 
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Fig. 2). Tubing is attached to the input and output channels. The input tubing is 
connected to a syringe pump (BS-8000, Braintree Scientific) delivering 
continuous flow of media (see below) to the top and bottom channels at a 
constant rate of 0.005 dyn/cm2 (11Jllmin). 
In vitro culture conditions (eBM) 
Four to eight weeks after implantation, the engineered bone marrow 
(eBM) was removed from the PDMS device, punctured in multiple places with a 
30G surgical needle, and cultured in a microfluidic device using HSC and 
hematopoietic progenitor media (SFEM basal media, StemCell Technologies) 
containing cytokines (50 ng/ml mouse SCF, 100 ng/ml mouse IL-11, 100 ng/ml 
mouse Flt-3 ligand, and 20 mg/ml human LDL). For experiments conducted in 
the absence of exogenous cytokines (Figure 12) hematopoietic progenitor media 
was used supplementation of cytokines. 
Bone marrow cell culture (Dexter Culture) 
Bone marrow stromal cells were harvested from 8- to 12-week-old 
C57BL/6 mice, re-suspended in DMEM medium (Gibco) containing 20% FBS 
(Gibco) , GlutaMAX (Gibco), and 100 units/ml penicillin-streptomycin (Gibco). 
The stromal cells were cultured on tissue culture plates (Falcon), changing the 
medium every other day. After the adherent monolayer became established 
(about 3 weeks), the cells were irradiated with 12 Gy. Bone marrow cells 
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harvested from femurs of C57BU6-Tg(UBC-GFP)30Scha/J mice were cultured 
on this bone marrow stromal cell layer using the same culture medium as is use 
in the microfluidic culture. 
Human umbilical cord blood (hCB) cells 
Fresh human umbilical cord blood was processed using Ficoii-Paque to 
fractionate mononuclear cells from the whole blood sample by density gradient 
centrifugation. Briefly, hCB was layered onto the Ficoii-Paque (GE Healthcare 
Life Sciences) gradient and spun (400 x g for 30 minutes at 20°(), separating the 
mononuclear cells from the plasma, granulocytes and erythrocytes. Cells were 
re-suspended in SFEM basal media (StemCell Technologies) containing 
cytokines including Flt-3 ligand, SCF, IL-3, and IL-6 contained in a pre-mixed 
product (StemSpan CC100, StemCell Technologies). For storage, cells were 
frozen in medium supplemented with 10% DMSO. 
In vitro culture conditions (hCB) 
Engineered bone marrow (eBM) harvested 8 weeks after implantation was 
removed from the PDMS device. We utilized two strategies to inactive the mouse 
immunologic system. The first included fixation in 4% PFA for 48 hours. The 
second strategy involved for transferred to medium designed to support human 
HSCs and hematopoietic progenitors, SFEM basal media (StemCell 
Technologies) containing cytokines including Flt-3 ligand, SCF, IL-3, and IL-6 
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contained in a pre-mixed product (StemSpan CC100, StemCell Technologies). 
One hour after incubation at 37C, the eBMs were exposed to 12Gy gamma 
radiation (Cs-137 source) to inactivate the mouse hematopoietic cells. After 
either inactivation strategy, the cells in the marrow compartment were flushed out 
using a 30G needle. 0.5 - 1 x 107 hCB mononuclear cells were seeded into the 
boney construct. The hCB-filled eBM was inserted into the microfluidic device for 
4 or 7 days of in vitro culture. 
In vivo engraftment assay 
Bone marrow transplantation 
Eight week old C57BU6J female mice (Jackson Laboratories) were 
irradiated with 12Gy (2 doses of 6Gy separated by 2-3 hours) using a Cs-137 
source. The bone marrow cells were harvested from femurs of C57BU6-Tg(UBC-
GFP)30Scha/J mice or from eBM produced in similar GFP-Iabeled mice after 4 or 
7 days of microfluidic culture. 2.5 x 1 05 bone marrow cells were delivered by 
intravenous (i.v.) tail vein injection within 12 hours of lethal irradiation. Animals 
were maintained on an antibiotic (Baytril, Bayer Corporation) to prevent bacterial 
infection related to radiation-induced immunosuppression. Engraftment was 
measured 6 weeks and 16 weeks after transplantation in peripheral blood 
collected by retro-orbital bleeds and evaluated by flow cytometric analyses to 
assess percent engraftment and degree of contribution to differentiated blood 
lineages. 
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RESULTS 
Engineering Ectopic Bone and Bone Marrow 
We sought to engineer an in vitro system that faithfully recapitulates or 
mimics the complete bone marrow microenvironment containing all component 
hematopoietic niches. To do so, we tested the hypothesis that leveraging existing 
bone tissue engineering techniques and combining them with microsystems 
strategies, we can produce bone containing a functional marrow in vivo that can 
be explanted intact and maintained in vitro under microfluidic culture conditions. 
In order to create ectopic bone containing marrow of a defined shape and 
size that is not imbedded inside tissue, we microfabricated devices using a 
biocompatible polymer polydimethylsiloxane (PDMS) [56], to serve as a mold 
inside which bone and bone marrow are induced to form (Figure 3A) . Our first 
implant device (implant design 1.0) was made with a central , cylindrical cavity 
open on both ends. The cavity is filled with bone-inducing materials, including 
DBP, BMP-2 and -4, and collagen type I, an effective carrier molecule used to 
ensure stability and prolonged delivery of the osteoinductive properties of the 
BMPs in coordination with natural bone matrix [57] (Figure 3B). The filled device 
is sutured to the surface of the muscle in the subcutaneous space on the back of 
a mouse, exposing the bone-inducing materials to the underlying muscle and 
underside (hypodermis) of the skin (Figure 3C). Four and 8 weeks after 
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implantation, the devices were harvested to evaluate extent of bone and bone 
marrow formation. 
Bone-Inducing 
Materials 
Figure 3. Implant design 1.0: Approach to ectopic bone marrow formation. (A) A 
cylindrical PDMS device shows central cavity (teal) into which bone inducing materials 
are embedded. (B) PDMS device containing bone inducing materials, before 
implantation. (C) Subcutaneous implantation in mouse. 
Our initial approach resulted in a limited amount of bone and bone marrow 
formation by 4 weeks, which showed a moderate increase by 8 weeks . 
Histological analysis revealed bone surrounding a small , discontinuous bone 
marrow compartment containing a strikingly low contribution of hematopoietic 
cells , compared to mouse femur bone marrow, that was heavily infiltrated by 
adipocytes (Figures 4, SA). The resulting bone marrow tissue constructs looked 
remarkably similar to the extent and structure of ectopic bone and bone marrow 
previously described , including the inordinate amount of adipocytes in the 
marrow [18, 19]. 
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Mouse Femur 
Figure 4. Implant Design 1.0: Histological representation of bone and bone 
marrow 4 and 8 weeks after implantation. Histological sections of the boney 
constructs harvested 4 (left) and 8 weeks (middle) after implantation reveal increasing 
amounts of bone (orange/pink) containing marrow that is heavily infiltrated with 
adipocytes (round empty spaces) and low contribution of hematopoietic cells, compared 
to mouse femur bone marrow (right). 
The presence of large numbers of adipocytes in the bone marrow can 
inhibit hematopoiesis [21]. Therefore, we sought to reduce adipocyte infiltration 
into the developing bone marrow to improve the hematopoietic composition of 
the marrow. In a second iteration of our design (implant design 2.0) , we covered 
the top of the device with a layer of PDMS, sealing the central cavity to restrict 
access of the overlying, adipocyte-rich hypodermis to the bone inducing 
materials, while maintaining direct contact with the surface of the muscle (Figure 
5). 
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Bone-inducing 
materials 
Subcutaneous 
implantation 
.. 
4 -8Weeks 
.. 
In vivo engineering 
of bone marrow 
Figure 5. Implant design 2.0: Improved approach to ectopic bone marrow 
formation. Representation of implantable PDMS device shows central cavity (teal) 
containing bone-inducing materials. The new design has included a layer of PDMS to 
seal off the top, skin-interfacing opening of the cavity. Devices are implanted 
subcutaneously in mice and harvested 4 or 8 weeks later. 
Subcutaneous implantation of this improved PDMS device resulted in the 
formation of a cylindrical disk of white boney tissue containing a central, blood-
containing marrow or 'engineered bone marrow' (eBM) over a period of 8 weeks 
(Figure SA, SB). Histological analysis confirmed the formation of bone by 4 
weeks (Figure SD), which appeared to be remodeled into a shell of cortical bone 
of relatively uniform thickness by 8 weeks (Figure SE). While a bone marrow 
compartment was present 4 weeks after implantation, it contained a significant 
number of adipocytes. By 8 weeks, hematopoietic cells, containing relatively few 
adipocytes, dominated the bone marrow. Comparison of histological sections of 
the engineered bone marrow made in the improved device 8 weeks after 
implantation (Figure SE), herein referred to as "eBM," to an intact femur (Figure 
SF) isolated from the same mouse confirmed that the morphology of the eBM 
was nearly identical to that of natural bone marrow. 
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A. B. 
Design 1.0 (8 wks) Design 2.0 (8 wks) 
• 
Figure 6- In vivo bone marrow engineering. (A) Photograph of eBMs implanted for 8 
weeks immediately after harvest in PDMS device design 1.0 (left) and 2.0 (right). (B) 
Photographs of engineered bone marrow made in implant device design 2.0, 4 and 8 
weeks after implantation. Low (left) and high (right) magnification views of histological 
H&E-stained sections of the engineered bone marrow formed in the (C) PDMS device 
design 1.0 after 8 weeks and the PDMS device design 2.0, (D) 4 and (D) 8 weeks after 
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implantation compared to (F) a cross-section of mouse femur bone marrow (bars, 50 
and 500 ~m for high and low magnification views, respectively) . 
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Evaluation of Bone Composition 
To characterize the architecture of the bone formed in our engineered 
tissue constructs, we utilized micro-computed tomography (micro-CT), a 
technique that generates a fully interactive three dimensional (30) reconstruction 
of a sample based on its ability to differentially transmit X-rays, which varies as a 
function of average electron density. In the case of our bone samples, the X-ray 
signal attenuation is greatest in the zones of mineralization, and not the 
surrounding soft tissue. 
Three-dimensional micro-CT reconstructions generated from the eBM 
demonstrated the formation of mineralized bone in samples harvested 4 and 8 
weeks after implantation (Figure 7 A). Direct comparison suggests that the bone 
underwent remodeling between 4 to 8 weeks of subcutaneous implantation. After 
8 weeks, the boney construct displayed an ordered internal trabecular network 
that closely resembles the intricate architecture found in normal adult mouse 
vertebral bone (Figure 7 A). 
Energy dispersive X-ray spectroscopy (EDS) is a method that focuses an 
electron beam onto a sample and measures scattered or dispersed X-rays 
ejected from the sample that have characteristic energies based on elemental 
composition. Using this technique, we conducted a compositional analysis of the 
eBM to evaluate the calcium to phosphorus ratio, compared to a mouse vertebra 
control. The analysis confirmed that the eBM generated in 8 weeks is 
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indistinguishable from natural trabecular bone in both the distribution and 
composition of the mineral phase (Figure 78, 7C). Together, these data 
demonstrate that our approach to subcutaneous bone tissue engineering 
resulted in the formation of cortical bone surrounding a trabecular bone network 
contained within the marrow compartment, all exhibiting a morphology and 
mineral composition that is consistent with native living bone. 
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Figure 7 - Engineered bone exhibits normal trabecular microarchitecture and 
mineralization. (A) 3D reconstruction of micro-CT data from eBM 4 (top) and 8 weeks 
(middle, bottom) following implantation. Note the ultrastructural similarities in both 
cortical and trabecular bone organization between the eBM 8 weeks after implantation 
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and a normal mouse vertebra. (B) Compositional backscattered scanning electron (BSE) 
micrographs and elemental mapping using energy dispersive x-ray spectroscopy (EDS) 
of cross sections of a mouse vertebra (left) and an eBM 8 weeks following implantation 
(right). Calcium and phosphorous EDS maps reveal similar uniform mineralization in 
both samples (bar, 1 mm). (C) Quantitation of the EDS analysis results analyzing the 
relative calcium and phosphorus composition in the samples from (B) confirm 
indistinguishable elemental compositions in the eBM compared to living bone (all error 
bars= standard error of the mean (S.E.M.)) . 
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Hematopoietic Populations in the Marrow of eBM 
To rigorously characterize the hematopoietic components of the 
engineered bone marrow, cells were harvested from the eBM immediately after 
surgical removal from the mouse and analyzed by flow cytometry to evaluate the 
expression patterns of surface antigen unique to subpopulations or 
hematopoietic cell type (Table 1). The hematopoietic cell composition of the 
eBM was compared to the distribution of hematopoietic populations in the bone 
marrow of mouse femurs and peripheral blood (Figure S). 
Devices harvested 4 or 8 weeks after implantation contained all blood cell 
types, including HSCs (Lin-sca1+cKit, "LSK") and hematopoietic progenitor cells 
(Lin-sca1+, un-cKit+, un-CD34+, un-CD135+) (Figure SA, SC), as well as both 
differentiated red (Ter119) and white blood cell lineages (T cells, CD45+CD3+; B 
cells, CD45+CD19+; myeloid cells, CD45+Mac1 +/-Gr1 +/-) (Figure SB, SO). 
The eBM harvested 4 weeks after implantation was only partially 
developed, as indicated by a lower proportion of HSCs and hematopoietic 
progenitor cells, compared to normal marrow (Figure SA, SC). However, cells 
harvested from the eBM at 8 weeks exhibited a distribution of HSCs, 
hematopoietic progenitors, and differentiated blood cells from all lineages that 
was nearly identical to that isolated from intact bone marrow (FigureS). These 
data demonstrate that we have engineered a cylindrical disk of bone resembling 
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natural cortical and trabecular bone (Figure 7) , which is filled with hematopoietic 
cells that are nearly identical in composition to natural bone marrow (Figure 8). 
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Figure 8- Hematopoietic composition of the engineered bone marrow. (A, C) 
Distribution of HSCs (Lin·sca 1 + cKit+, green) and hematopoietic progenitor cells (Lin· 
Sca1+, cyan; Lin·cKit+, purple; Lin.CD34+, red; Lin-CD135+, blue) as quantified by flow 
cytometric analysis of fresh, uncultured, mouse bone marrow (mBM) from adult femur, 
eBM at 4 (eBM 4wk) or 8 weeks (eBM 8wk) after implantation, or mouse peripheral 
blood (mPB) that underwent erythrocyte lysis to facilitate detection of rare HSCs. (8, D) 
Distribution of erythrocytes (Ter119+, blue), myeloid cells (CD45+Mac1 a+, red; 
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CD45+Gr1+, green; CD45+Mac1+Gr1+, purple), 8 cells (CD45+CD19+, cyan) and T cells 
(CD45+CD3+, orange) in mBM (n=6), eBM 4 wk (n=5), eBM 8 wk (n=5) and intact mPB 
(n=1 ). 
30 
Chemokines of the Bone Marrow Hematopoietic Niche 
The CXC cytokine ligand 12 (CXCL 12), also known as Stem Cell Derived 
Factor- 1 (SDF-1), is expressed on a variety of cell types in the bone marrow 
including, osteoblasts [47], perivascular endothelial and perivascular stromal 
cells [32]. Interaction with its cognate receptor, CXC chemokine receptor 4 
(CXCR4), expressed on hematopoietic stem and progenitor cells is critical to the 
recruitment, retention and maintenance of HSCs [32, 58-60]. Given the 
importance of this receptor-ligand pair to the composition and function of 
hematopoietic cells found in the bone marrow we interrogated the expression 
and localization of CXCL 12 and CXCR4 by immunohistochemistry. Our analysis 
confirmed that CXCL 12 is indeed expressed in the eBM, localizing to cells 
including those lining the inner surface of the bone and blood vessels. CXCR4, 
was expressed by clusters of lymphoid cells near the endosteal and perivascular 
niches (Figure 9). 
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Figure 9- Immunohistochemical analysis of CXCL 12 and CXCR4 in eBM. CXCL 12 
is expressed in the (A) eBM and in (C) mouse femur (femur) by cells of the endosteal 
and perivascular niche. CXCL 12's cognate receptor, CXCR4, is expressed by clusters of 
lymphocytes in the (B) eBM and in (D) in mouse femurs (femur). Images are taken at 
63X magnification. 
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In vitro Maintenance of eBM 
To determine whether the hematopoietic microenvironment contained 
within the eBM can maintain the blood constituents of the marrow in vitro, we 
designed a microfluidic culture system to enable sterile culture of the tissue 
construct under continuous flow of media (Figure 10). The microfluidic device is 
made of three PDMS layers, including a top and bottom channel, separated by 
two porous PDMS membranes (100 om diameter pores) (Figure 10A). After 
surgical removal of the eBM from the implanted device, the tissue was introduced 
into the central well (middle layer) of the microfluidic device, stacked between the 
porous membranes and channels, and connected to tubing to enable perfusion of 
the tissue from the top and bottom. 
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Figure 10- Microfluidic culture system designed to maintain eBM in vitro. (A) 
Diagrammatic display of microfluidic designed for in vitro culture of eBM formed in vivo. 
The microdevice is made of three PDMS layers, including a top and bottom channel, 
separated by two porous PDMS membranes (100 o m diameter pores) . (B) Photograph 
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of the bone marrow chip microdevice used to culture the eBM in vitro. (bottom; bar, 2 
mm) 
To test our bone marrow microfluidic culture system, eBM formed in vivo 
for 8 weeks was surgically removed from the mouse, punctured in multiple places 
with a surgical needle to permit fluid access, and cultured in the microfluidic 
device in serum-free medium supplemented with cytokines (Fit-3 ligand, IL-11, 
LDL and SCF) known to support HSCs and progenitor cells in vitro [61, 62]. In 
vitro assays currently used to test drug efficacies and toxicities on bone marrow 
require a minimum of 4 days of cell culture [63, 64]. Therefore, we cultured the 
eBM for 4 and 7 days within the bone marrow-on-a-chip system, harvested the 
marrow, and characterized the hematopoietic populations by flow cytometry. For 
comparison, bone marrow was harvested from normal mouse femurs and 
maintained for 4 and 7 days on a 2D stromal 'feeder' cell layer (Dexter-type 
culture), the benchmark for maintaining survival of HSCs and hematopoietic 
progenitor cells in vitro [8, 65]. 
Our analysis revealed that there was no significant difference in cell 
viability of hematopoietic cells in the eBM after 4 or 7 days of culture in the 
microfluidic device, compared to the Dexter culture (Figure 11A). Quantification 
of the hematopoietic populations remaining in Dexter culture after 4 and 7 days 
demonstrated a significant decrease (p < 0.0005) in the number of long-term 
HSCs (Lin-CD150+ CD48- cells) and a concomitant increase (p < 0.0005) in the 
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number of hematopoietic progenitor cells (Lin-CD34+, Lin-sca1+, un-cKit) relative 
to the number found in normal mouse bone marrow, as previously reported [8-11] 
(Figure 11 B, 11 C). These data suggest that the long-term HSCs -the cells 
capable of multi-potency, long-term self-renewal and differentiation into a// blood 
cell types-- are differentiating into short-term, lineage-restricted progenitor cells 
in the static Dexter culture system, underscoring the inherent difficulty of 
maintaining HSCs in conventional in vitro culture systems. 
In contrast, flow cytometric analysis revealed that the number and 
distribution of HSCs and hematopoietic progenitor cells in the eBM cultured for 4 
and 7 days on-chip remained very similar to the proportions displayed by freshly 
harvested mouse femur bone marrow (Figure 11 C). Importantly, the bone 
marrow-on-a-chip also enabled maintenance of a significantly higher (p < 0.0005) 
proportion of long-term HSCs, compared to the Dexter Culture (Figure 11 B). 
These data suggest that the microengineered bone marrow-on-a-chip device 
contains a functional hematopoietic microenvironment that can be maintained for 
at least 7 days in culture under microfluidic flow in vitro, representing a significant 
improvement over conventional Dexter culture of HSC and hematopoietic 
progenitor cells. 
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Figure 11. In vitro microfluidic culture of eBM within the bone marrow-on-a-chip. 
(A) Viability of cells isolated from uncultured mouse femur bone marrow (mBM), femur 
bone marrow cultured for 4 and 7 days on a stromal cell layer in a Dexter culture (mBM, 
04 & 07), eBM cells analyzed immediately after surgical removal (eBM), and eBM cells 
after 4 and 7 days of culture on-chip (eBM, 04 & 07). (n=7) (B) Percentage of long-term 
HSCs (Lin-CD150+CD48-) present in marrow after 4 and 7 days in Dexter culture (mBM, 
04 & 07) versus eBM cultured in the bone marrow-on-a-chip (eBM, 04 & 07) compared 
with freshly harvested eBM or mBM (*p < 0.0005; n=7). (C) Proportion of HSCs (Lin· 
Sca1 +cKi( cells , green) and hematopoietic progenitor cells (Lin·sca1 +, cyan; Lin-cKit, 
purple; Lin-CD34+, red; Lin-CD135+, blue) in the mBM and eBM populations at the time of 
isolation compared to 4 and 7 days of culture (n=7). 
Sustained maintenance of a fully functional hematopoietic system requires 
the support of the bone marrow hematopoietic microenvironment in its entirety. 
Our assessment of the bone and blood composition of the eBM suggests that we 
have recapitulated the complex environment of the bone marrow. To evaluate 
whether or not the complement of critical inductive cues necessary to support 
hematopoiesis are actively produced within the eBM, we tested the ability of the 
eBM to support HSC and hematopoietic progenitors in the microfluidic culture 
system for 4 and 7 days in serum-free medium in the absence of supplemental 
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cytokines known to support HSC and hematopoietic progenitors. 
In the Dexter culture system, removal of the HSC and progenitor-
supporting cytokines from the culture media altered the distribution of HSCs and 
hematopoietic progenitors, reducing the overall contribution of these primitive 
populations (Figure 12A). This suggests that the environment offered by the 
Dexter culture system is unable to fully regulate self-replication, proliferation and 
differentiation of the primitive hematopoietic populations, leaving them vulnerable 
to stimulation by exogenous cytokines. In the eBM, the distribution of the HSCs 
and progenitor populations remained similar when maintained in the microfluidic 
culture system for up to 7, days with or without supplemental cytokines (Figure 
128). Taken together, these data demonstrate that the hematopoietic 
.microenvironment of the eBM can support and regulate the hematopoietic 
populations in an autonomous fashion , suggesting the presence of a collection of 
hematopoietic niches that cooperate to regulate the hematopoietic composition of 
the bone marrow. 
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Figure 12. In vitro culture of eBM in the absence of supplemental cytokines. 
Proportion of HSCs (Lin-sca1+cKit, "LSK" cells, green) and hematopoietic progenitor 
cells (Lin-sca1+, blue; Lin-cKit, red; Lin-CD34+, purple) in (A) Dexter culture (mBM) and 
(B) eBM after 4 (04) and 7 days (07) in culture in the presence(+ cytokines) and 
absence (no cytokines) of supplemental cytokines (Fit-3 ligand, IL-11, LDL and SCF) 
(n=3). 
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In Vivo Reconstitution Assay 
To unequivocally confirm the presence of functional HSCs and 
hematopoietic progenitor cells cultured in the bone marrow-on-a-chip, it is 
necessary to demonstrate self-renewal and differentiation capabilities by testing 
their ability to reconstitute blood formation in vivo. 
To meet this challenge, we created eBM in transgenic mice that expresses 
green fluorescent protein (GFP) under the control of the human ubiquitin C 
promoter, driving the expression of the fluorescent protein in all cells, with 
especially high levels of expression in the hematopoietic system [66]. Bone 
marrow cells harvested from the GFP+ eBM maintained in culture in the 
microfluidic system for 4 days or from freshly harvested GFP+ mouse femurs 
were delivered (2.5 x 105 cells I mouse) intravenously into syngeneic mice that 
received a lethal dose of y-irradiation (12 Gy) to deplete hematopoietic function 
of the host bone marrow. Total engraftment was assessed through quantification 
and characterization of donor-derived (GFP+) hematopoietic cells in the 
peripheral blood 6 and 16 weeks after transplantation to confirm the presence of 
functional hematopoietic progenitor cells and HSCs from the donor sample, 
respectively. 
Cells harvested from the eBM following 4 days in the microfluidic culture 
on-chip successfully engrafted in the mice at a similar rate as fresh, uncultured 
mouse femur bone marrow, showing 70% and 85% engraftment by 6 and 16 
39 
weeks after transplantation, respectively (Figure 13A). Furthermore, the 
transplanted cells from the cultured eBM populated all lineages of differentiated 
blood cells (Figure 138). These data confirm the presence of functional 
hematopoietic progenitor and multipotent, long-term HSCs in the eBM and 
suggest that abundance of these repopulating cells is comparable to freshly 
harvested bone marrow after 4 days of culture in the microfluidic system. 
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Figure 13. Bone marrow transplantation to evaluate presence of functional HSCs 
and hematopoietic progenitors. (A) Extent of bone marrow engraftment in lethally 
irradiated mice transplanted with 2.5 x 105 GFP• cells from fresh mouse bone marrow 
(mBM) or isolated from the eBM following 4 days of in vitro culture on-chip (eBM D4). 
Engraftment is presented as percentage of GFP+ cells in the lymphoid population 
(CD45+) of peripheral blood measured 6 weeks and 16 weeks after transplantation to 
confirm retention of functional short- and long-term HSCs, respectively. (B) Distribution 
of differentiated blood cells within the engrafted CD45+ population from mBM and eBM 
D4 transplants 6 and 16 weeks after transplantation. Differentiated cell types include T 
cells (CD4s•co3•, purple), B cells (CD45.CD19•, green) and myeloid cells (CD45. Gr1 ·, 
red; CD45.Mac1 •, blue). 
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Maintenance of Human Umbilical Cord Blood in eBM 
The development of an in vitro platform that can successfully maintain the 
mouse bone marrow microenvironment and its hematopoietic contents, including 
multipotent, self-replicating HSCs and progenitors, suggests the potential for a 
translational application as a system to culture and maintain human blood 
. equivalents for pharmaceutical or therapeutic applications. While there have 
been innumerable attempts and reports of human HSC expansion in vitro, these 
studies typically fail to achieve the intended goal of scaling production of true, 
functional, HSCs (e.g. a lack robust multi-lineage engraftment [67]). Given the 
clinical efficacy [68] and frequency of hematopoietic stem cell transplants (HSCT) 
procedures (numbering over 50,000 world wide in 2006 [69] and increasing ever 
since) and the growing dependence on umbilical cord blood (hCB) a source, a 
tool that could maintain -- or even induce -- self-renewal of human hematopoietic 
stem cells for transplantation would be of great translational value [62]. Beyond 
direct clinical applications, an in vitro system that reliably recapitulates the 
behavior of human bone marrow may prove to be an asset for the 
pharmaceutical industry to facilitate reliable predictions of the efficacy of drugs 
for hematopoietic diseases or screen for potential bone marrow toxicity in drugs 
under development. 
We conducted a set of preliminary experiments to test the ability of the 
eBM to support human HSCs and hematopoietic progenitors derived from a 
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source rich in these primitive populations, umbilical cord blood (hCB). 
Mononuclear cells were recovered from fresh umbilical cord samples by Ficoll-
Paque gradient centrifugation. Following surgical removal of the eBM, we 
attempted two methods of eBM preparation for seeding of the hCB cells. 
In the first method, we harvested the eBM after 8 weeks and fixed the 
tissue construct in 4% paraformaldehyde (PFA) to ensure complete inactivation 
of the mouse cells in order to prevent an immune reaction from being mounted 
by residual mouse blood. After fixation, the mouse marrow contained within the 
eBM was physically flushed out of the mouse bone using a 30G needle to create 
space to accommodate seeding of the hCB. After cell seeding into the fixed 
tissue, the hCB-filled eBM was introduced into the microfluidic device (Figure 1 0) 
for 4 or 7 days of culture. 
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Figure 14. In vitro maintenance of human umbilical cord blood (hCB) in fixed 
eBM. (A) Viability of hCB measured by propidum iodide (PI) staining after 4 and 7 days 
in dish culture (Dish 04 & 07) or eBM cultured in the bone marrow-on-a-chip (eBM 04 & 
07) compared with freshly harvested hCB (n=S) (B) Percentage of long-term HSCs (Lin-
CD38-CD90+) present after 4 and 7 days in dish culture or eBM cultured in the bone 
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marrow-on-a-chip, compared with freshly harvested hCB (n=5). (B) Percentage of 
hematopoietic stem I progenitors (Lin-CD34+) present after 4 and 7 days in dish culture 
or eBM cultured in the bone marrow-on-a-chip, compared with freshly harvested hCB 
(n=5). 
Flow cytometric analysis (Table 2) of hCB following 4 and 7 days in 
culture demonstrated that there was no significant difference is cell viability 
between traditional dish culture and eBM-on-a-chip system (Figure 14A). 
Evaluation of long-term HSCs (Lin-CD38-CD90+) showed that the eBM conferred 
an advantage over traditional dish culture in maintaining these cells. However, 
there appeared to be significantly more stem/progenitor CD34+ (Lin- CD34+) in 
dish culture, compared to eBM. Considering that CD34 is a relatively 
promiscuous marker expressed by stem and progenitor cells, this may suggest 
that the bona fide HSCs are differentiating in the artificial environment offered by 
tissue culture plastic. Due to the difficulty of seeding the hCB into the small 
marrow compartment of the eBM, technical improvements are required to 
increase the reproducibility of the method and thus reduce variability in our 
results. 
The second method we employed was the use of y-radiation (12 Gy) , 
instead of PFA fixation, to inactivate but retain live mouse cells. Following 
radiation, the same procedure was completed, including flushing the 
hematopoietic cells out of the eBM, seeding of hCB mononuclear cells, followed 
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by introduction into the microfluidic culture system for maintenance under 
constant flow for 4 and 7 days. 
Using this approach, flow cytometric analysis revealed a decrease in hCB 
long-term HSCs (Lin-CD38-CD90+) between 4 and 7 days in traditional dish 
culture (Figure 15A). In the eBM microfluidic culture system, there appeared to 
be an initial reduction in HSCs that remained stable between 4 and 7 days in 
culture. Evaluation of hematopoietic stem I progenitor population (Lin-CD34+) 
showed an initial increase in both dish and eBM culture systems by 4 days that 
was reduced by 7 days in dish culture but continued to increase in the eBM 
(Figure 148). Given that these preliminary results represent data from one 
experiment, the replication is required before conclusions can be drawn. 
A. B. 
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Figure 15. In vitro maintenance of human umbilical cord blood (hCB) on irradiated 
eBM. (A) Percentage of long-term HSCs (LhCD38-CD90+) present after 4 and 7 days 
in dish culture (Dish D4 & D7) or eBM cultured in the bone marrow-on-a-chip (eBM D4 & 
D7) compared with freshly harvested hCB (n=1 ). (B) Percentage of hematopoietic stem 
I progenitors (Lin-CD34+) present after 4 and 7 days in dish culture (Dish D4 & D7) or 
eBM cultured in the bone marrow-on-a-chip (eBM D4 & D7) compared with freshly 
harvested hCB (n=1 ). 
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DISCUSSION 
The bone marrow-on-a-chip microtechnology described here provides an 
important proof-of-concept for the creation of a system that recapitulates the 
complex bone marrow microenvironment in its entirety that can be maintained 
outside of a living animal, in vitro. By leveraging microfluidic strategies, this 
platform enables control of the naturally existing interdependent, distinct 
anatomical hematopoietic niches in the bone marrow, offering a powerful tool to 
maintain the complete collection of hematopoietic populations in the correct 
proportions to model and study hematopoiesis at a tissue level. Furthermore, it 
may offer translational value by serving as an in vitro alternative to test and 
predict efficacy or toxicity of drugs targeting the bone marrow, maintenance or 
manufacture of blood populations for therapeutic applications, or even as an in 
vitro diagnostic system. 
The approach described here differs from conventional tissue engineering 
approaches in which materials or living cells are implanted in vivo without 
geometric constraint, and often embedded within tissues of living animals, 
offering little control over the environment in which the heterotopic or ectopic 
tissue is induced to form. By utilizing a biocompatible polymer, PDMS [56], that is 
FDA-approved for use in implantable prosthetic devices in humans (e.g., breast 
prostheses), we have created a flexible mold that can be filled with limitless 
combinations of tissue-inducing biomaterials while offering control over the 
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localization and dimensions of the resulting tissue. Illustrated by our design 
modifications (implant design 1.0 vs. implant design 2.0) of the implantable 
PDMS device (Figures 3, 5), the ease with which the moldable material can be 
re-designed and tested offers a moderate throughput approach to iterative design 
improvements. The flexibility of the system is further enhanced by the adjustable 
parameters of the in vitro microfluidic culture system, including delivery rate and 
content of culture medium. 
The initial design of the PDMS implant created to produce ectopic bone 
marrow yielded only moderate success, inducing modest bone formation 
surrounding a marrow cavity heavily populated with adipocytes and relatively low 
hematopoietic cell content, compared to mouse femur bone marrow (Figure 4). 
Given the negative influence adipocytes exert on hematopoiesis in the bone 
marrow [21], we sought to improve the design by covering the cavity containing 
the bone-inducing materials with a layer of PDMS. Our original hypothesis was 
that physical restriction of the adipocytes in the overlying hypodermis from the 
bone-inducing materials would reduce the number of resident adipocytes that 
migrated into the engineered marrow. While the second design achieved the 
desired result (Figure 6C, 6E), we cannot eliminate the possibility that sealing 
the top of the cavity effectively altered its chemical (pH, oxygen tension, etc.) 
and/or physical milieu and induced the infiltrating undifferentiated mesenchymal 
cells recruited to the osteoinductive material toward an osteoprogenitor instead of 
an adipocyte fate (Figure 16) [14, 70-72] . 
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Figure 16 - Osteogenic vs. adipogenic potential of bone marrow undifferentiated 
mesenchymal cell. Diagram illustrating the ability of the undifferentiated mesenchymal 
cells from adult bone marrow to undergo differentiation into the osteogenic lineage 
versus the adipogenic lineage. Modified from Bianco et al. [70] 
The compositional analysis of the resulting eBM generated 4 and 8 weeks 
after implantation in our improved device (Figure 5) suggests the formation of 
ectopic bone induced in the device undergoes a remodeling process between 4 
and 8 weeks to produce tissue whose architectural and mineral content are 
nearly indistinguishable from natural bone (Figure 7). In parallel with the 
structural maturation of the bone between 4 and 8 weeks of implantation , the 
distribution of the hematopoietic content of the marrow also changed , more 
closely matching that of naturally existing femur bone marrow by 8 weeks 
(Figure 8). This 'normalization' of the eBM suggests that the bone and bone 
marrow formation in the ectopic compartment follows a coordinated process or 
program inherent to the collection of infiltrating niche-forming cells executed 
·· ~· according to the dynamically changing local cues within the artificial, implanted 
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device [15-17]. This observation underscores the critical importance and power 
conferred by the physical microenvironment or niche to an incompletely 
differentiated cell in regulating its ultimate lineage fate and function and supports 
the broadly accepted dogma that "structure equals functions. " Perhaps we can 
now include "fate," and propose that "structure equals function and dictates fate" 
in the case of incompletely differentiated cells . 
In the context of the eBM, our work implies that a cell or collection of cells 
(e.g., multipotent mesenchymal cell) originating in muscle tissue proximal to the 
morphogen rich bone-inducing material, moves into this defined environment and 
is provided with a sufficient amount of guidance or information to begin a process 
(differentiation, expression and secretion of bioactive molecules, recruitment of 
additional cells, etc.) ultimately resulting in the formation of the extraordinarily 
complex bone marrow niche that is nearly identical to what develops in a whole 
animal as a result of highly regulated developmental program. 
The incredible influence that a microenvironment has on the fate and 
function of an incompletely differentiated cells underscores the extraordinary 
potential of the eBM in the context of hematopoiesis. Complete reconstruction of 
the tightly regulated , extremely complex milieu of natural bone marrow enables 
us to leverage natural biological programs that have evolved over millions of 
years to create the ideal environment to support the hematopoietic system, 
maintaining all blood populations in the correct ratios. What could possibly be 
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better than a nearly exact replica of its actual environment for maximal retention 
of function outside of a living animal? 
Indeed, we found that when removed from the host animal and introduced 
into a microfluidic culture system, the eBM maintained the full complement of 
hematopoietic cells in normal proportions for at least one week in culture, 
including functional self-replicating, multipotent HSCs and hematopoietic 
progenitors cells in culture better than other in vitro methods (Figures 11, 13). 
Even in the absence of exogenous cytokines that are shown to be important 
regulators of HSCs and progenitors, the eBM alone behaved in a functionally 
autonomous fashion to maintain the stem and progenitor populations in normal 
ratios (Figure 12). 
In light of the potential translational applications for the bone marrow-on-a-
chip microtechnology, we attempted two strategies, chemical fixation (Figure 14) 
or y-irradiation (Figure 15), to disable the mouse immunologic response to 
enable the use of the mouse eBM to culture human umbilical cord blood-derived 
mononuclear cells. Using a fixation-based protocol, we show that even in the 
absence of live cells, the 30 architecture of the eBM showed a trend towards a 
modest advantage compared to traditional to dish culture in maintaining human 
long-term HSCs in vitro. The very preliminary data we collected using radiation 
protocol suggested that over longer periods in culture, there may be a trend 
towards improved maintenance of HSCs and progenitors by the inactivated, live 
mouse hematopoietic niched, though no real conclusion can be drawn in the 
49 
absence of additional data. These methods require significant optimization to 
standardize the approach to reduce variability and improve the functional 
outcome. 
The bone marrow-on-a-chip microtechnology is made possible by truly 
working at the intersection between of engineering and biology to leverage and 
improve existing strategies for new purposes. Learning from fields ranging from 
bone engineering, developmental , stem cell, bone and blood biology, as well as 
microfluidic engineering, we have combined a diverse set of techniques to take 
advantage of natural mammalian biology to replicate the complexity of real, 
functional bone marrow. Our system offers a tool to enable a degree of discovery 
and mechanistic understanding not otherwise possible in vitro. While much work 
remains to adapt the system for human-specific applications, this work offers an 
important first step in harnessing the power of microtechnology to influence the 
function and fate of hematopoietic cells. 
FUTURE DIRECTIONS 
By engineering whole bone marrow in vivo, we have recreated the entire 
hematopoietic microenvironment enabling in vitro maintenance of a functional, 
proportionally sound hematopoietic system. Furthermore, we demonstrate that 
the eBM can autonomously produces the factors necessary to support the 
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maintenance and function of the hematopoietic system, thus relieving the 
dependence of expensive supplemental cytokines to ensure maintenance of all 
hematopoietic populations, including HSCs and hematopoietic progenitor cells. 
This may prove to be a major advantage, enabling functional bone marrow 
studies of extended duration in vitro that would otherwise be cost-prohibitive. 
The bone marrow-on-a-chip also may serve as a platform for the 
expansion or production of specific types of blood cells by modifying the medium 
and adding appropriate cytokines (e.g., HSCs 10, erythropoietin28 to form red 
blood cells; thrombopoietin29 to form platelets; GM-CSF to form white blood cells) 
and collecting cells from the outflow for off-chip use and analysis. This could 
eventually lead to the production of blood replacements for patients with a wide 
variety of hematologic diseases ranging from cancer to anemia. 
It is also important to note that the ability to produce trabecular bone with 
architectural and compositional properties similar to natural bone offers a new 
way to produce bones of pre-defined size and shape, and therefore serve as a 
tool to study bone biology, remodeling, and bone pathophysiology in vitro. 
Given the completeness of the bone marrow hematopoietic 
microenvironment within the eBM, the system may be useful to mimic the 
complex tissue-level responses of normal marrow to radiation toxicity, medical 
countermeasures that might protect against radiation poisoning, or other drugs 
under development, thus becoming a valuable in vitro replacement for whole 
animals. In addition, the possibility of visualizing and studying the intact bone 
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marrow niche in situ over time could provide entirely new ways to evaluate the 
effects of drugs and toxins on hematopoiesis, as well as to model complex 
hematologic diseases in vitro. 
While we show preliminary strategies attempted to create a human model 
system, one could envision using alterative methods including engineering the 
eBM in immunocompromised mice (e.g., NOD.Cg-Prkdcscid 112rgmtwp/Sz; NSG) 
and replacing the mouse marrow with human hematopoietic cells. By humanizing 
our platform, we could conduct patient-specific drug screening to identify the 
most effective drug to treat a patients hematologic disease and provide 
pharmaceutical companies with a tool for reliable drug screening before entering 
clinical trials. 
The bone marrow-on-a-chip offers a powerful tool to accelerate discovery 
and development in a wide range of biomedical fields ranging from hematology, 
oncology, and drug discovery to tissue engineering. 
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